Pegylated liposomal doxorubicin (Peg-LD) and paclitaxel in patients with metastatic breast carcinoma: A phase II study

884 Introduction: Systemic chemotherapy has saved the life of many patients with cancer, but the maximum efficacy of cytotoxic agents is severely limited by their adverse effects. Peg-LD has the advantage of delivering the active anthracycline directly to the tumor site while exposing the patient to a lesser degree of doxorubicin-associated toxicities. More recently, a regimen in which Paclitaxel is infused weekly over 1 hour produced substantial anti-tumor activity, with little myelosuppression. Materials and Methods: We designed a phase II trial to study the efficacy and toxicity of Paclitaxel 70 mg/m2 weekly in metastatic breast cancer patients with high cardiologic risk. All patients were premedicated with Pyridoxine 300 mg/daily per os and Desametasone 8 mg i.v. before each chemotherapy administration to prevent the palmar-plantar erythrodysesthesia (PPE). To date, 15 pts have been recruited, 12 pts (80%) evaluable for efficacy and 15 pts (100%) for toxicity. Adjuvant chemotherapy had been administer...